SCHEMBL854946

SCHEMBL854946

Fc1cc(Br)cc(I)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29543031 1.00
SCHEMBL1229565 0.78
SCHEMBL782213 0.78
SCHEMBL491373 0.78
SCHEMBL504770 0.78
SCHEMBL18335412 0.78
SCHEMBL369162 0.78
SCHEMBL1274784 0.76 CA12 (0.42)
Phosphine SCHEMBL28192310 0.76 CA12 (0.42)
SCHEMBL9397842 0.76 TTR (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260068426-A1 LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE CONDENSED CYCLIC COMPOUND SAMSUNG DISPLAY CO LTD (KR) 2026-03-05 US disclosed
EP-4703406-A1 HYDROLYZABLE SILYL GROUP-CONTAINING POLYOXYALKYLENE POLYMER, CURABLE COMPOSITION, AND CURED PRODUCT Kaneka Corporation (JP) 2026-03-04 EP disclosed
EP-4703367-A1 RUTHENIUM COMPLEX, METHOD FOR PRODUCING SILYL GROUP-CONTAINING COMPOUND, SILYL GROUP-CONTAINING POLYMER MIXTURE, CURABLE COMPOSITION, AND CURED PRODUCT Kaneka Corporation (JP) 2026-03-04 EP disclosed
US-20260049182-A1 RUTHENIUM COMPLEX, METHOD FOR PRODUCING SILYL GROUP-CONTAINING COMPOUND, SILYL GROUP-CONTAINING POLYMER MIXTURE, CURABLE COMPOSITION, AND CURED PRODUCT KANEKA CORPORATION (JP) 2026-02-19 US disclosed
US-20260049176-A1 HYDROLYZABLE SILYL GROUP-CONTAINING POLYOXYALKYLENE POLYMER, CURABLE COMPOSITION, AND CURED PRODUCT KANEKA CORPORATION (JP) 2026-02-19 US disclosed
EP-4696316-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 EP disclosed
US-20260042740-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-12 US disclosed
EP-4054719-B1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-11 EP disclosed
US-12415770-B2 Modulators of liver receptor homologue 1 (LRH-1) and uses Emory University, Office of Technology Transfer (US) 2025-09-16 US disclosed
US-12384750-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-08-12 US disclosed
EP-2375904-B1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME (US) 2014-05-28 EP disclosed
WO-2014005217-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2014-01-09 WO disclosed
US-20130188107-A1 LIQUID-CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2013-07-25 US disclosed
WO-2013049332-A1 INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE INFINITY PHARMACEUTICALS, INC. (US) 2013-04-04 WO disclosed
US-8409673-B2 Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical device JNC CORPORATION (JP) 2013-04-02 US disclosed
US-20120099039-A1 CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2012-04-26 US disclosed
EP-2433923-A1 CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL ELEMENT JNC Corporation (JP) 2012-03-28 EP disclosed
CN-102388013-A Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical element JNC CORP 2012-03-21 CN disclosed
CN-102203058-A Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders ACUCELA INC 2011-09-28 CN disclosed
US-20100093865-A1 SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-04-15 US disclosed